A device and method for evaluating in vitro drug absorption under ultragravity

Abstract

This invention discloses a device and method for evaluating in vitro drug absorption under hypergravity conditions, belonging to the field of medical device technology. The device structure includes: a centrifuge, a centrifuge container, and drug absorption evaluation unit units. Each centrifuge container contains multiple sequentially arranged drug absorption evaluation unit units. Each drug absorption evaluation unit includes a supply chamber, a receiving chamber, an intestinal explant, and a microporous mesh. The supply chamber and receiving chamber are positioned opposite each other, with the intestinal explant sandwiched between them. The supply chamber has at least one supply channel, and the receiving chamber has a receiving cavity paired with the supply channel. Each receiving cavity is topped with a microporous mesh to inhibit deformation of the intestinal explant under hypergravity conditions. This device combines structural simplification, preservation of physiological relevance, and ease of detection. Combined with a spectral correction model, it enables accurate and reliable in vitro hypergravity drug absorption studies.

Description

Technical Field

[0001] This invention belongs to the field of medical device technology, specifically relating to a device and method for evaluating in vitro drug absorption under ultragravity. Background Technology

[0002] Oral administration is one of the most common routes of drug delivery. The absorption efficiency of drugs in the intestine directly affects their bioavailability in vivo. Therefore, establishing a reliable in vitro drug absorption evaluation system is crucial for systematically analyzing drug absorption behavior in the intestine, elucidating transmembrane transport mechanisms, and assisting in drug screening and early-stage development. It helps assess absorption characteristics in the early stages of drug development, reducing the risk of later clinical failures, and is a key step in improving the efficiency and success rate of drug development.

[0003] Several in vitro drug absorption evaluation schemes have been proposed in the prior art. For example, patent document CN115235969A discloses a method for evaluating drug permeability in the small intestine, which uses small intestinal organoid cells and Caco-2 cells co-cultured in a device to form a dense cell layer to simulate the small intestinal wall, and performs drug permeability tests to assess drug transmembrane permeation behavior. Patent document CN220961107U discloses a drug transmembrane permeation experimental device, which integrates a diffusion cell, a gas supply system, and a fluid-driven structure to realize drug permeation research based on a cell model under in vitro conditions. The above technical solutions mainly revolve around in vitro cell barrier models and their supporting experimental devices, thereby realizing the study of drug permeation behavior across biological barriers under in vitro conditions.

[0004] However, the above methods still have some shortcomings, mainly in the following aspects: First, most existing evaluation methods are based on cell layer models formed by co-culturing Caco-2 cells or organoid cells, which are essentially still cell layer barrier models and are difficult to reflect the complex characteristics of real intestinal tissue in terms of structural hierarchy and tissue microenvironment; Second, some devices achieve automated culture and detection by integrating gas supply systems, pressurization mechanisms, solenoid valves and multiple sensors. Although this improves the system's functional integration, the overall structure is complex, the volume is large, and the engineering implementation and maintenance costs are high, which is not conducive to rapid deployment in the laboratory and is also difficult to be compatible with conventional mechanical loading methods (such as centrifuge equipment); Third, existing in vitro drug absorption evaluation methods are mainly carried out under normal gravity conditions, and there are relatively few systematic studies on hypergravity environmental factors. Although a few studies have attempted to carry out related experiments under hypergravity conditions, they usually rely on large-scale dedicated centrifuge devices. The experimental systems are large and complex, making it difficult to meet the needs of flexible deployment and in vitro drug absorption evaluation under conventional laboratory conditions. Fourth, in the drug concentration detection process, existing methods usually rely heavily on complex analytical equipment such as liquid chromatography-mass spectrometry, which has high requirements for experimental conditions and detection platforms, thus limiting their promotion in rapid screening and engineering applications.

[0005] Therefore, there is an urgent need to develop a device and method for evaluating in vitro drug absorption under hypergravity conditions, in order to achieve controllable hypergravity loading under conventional laboratory conditions and to evaluate the in vitro drug absorption behavior of intestinal tissue in a hypergravity environment. Summary of the Invention

[0006] To address the shortcomings of the existing technologies, this invention provides a supergravity in vitro drug absorption evaluation device that combines structural simplification, preservation of physiological relevance, and ease of detection.

[0007] The specific technical solution adopted is as follows: A supergravity in vitro drug absorption evaluation device includes: a centrifuge device, a centrifuge container, and a drug absorption evaluation device unit; each centrifuge container has multiple drug absorption evaluation device units arranged in sequence inside. The drug absorption evaluation device unit includes a supply chamber, a receiving chamber, an intestinal explant, and a microporous mesh. The supply chamber and the receiving chamber are arranged opposite each other, with the intestinal explant sandwiched in between. The supply chamber is provided with at least one supply channel, and the receiving chamber is provided with a receiving cavity that matches the supply channel. Each receiving cavity is provided with a microporous mesh above it to suppress the deformation of the intestinal explant under hypergravity conditions. At least one openable and closable sampling hole is provided on the lower side wall of the receiving chamber. The sampling hole communicates with the lower part of the receiving cavity and remains sealed when no sampling is being performed. Intestinal explants are prepared by washing animal jejunal tissue after removing the serosa and muscle layers.

[0008] Specifically, the drug absorption evaluation device unit also includes a fixing component that fixes the supply chamber, the receiving chamber, and the intestinal explant in relative positions.

[0009] Furthermore, the fixing element is a ring magnet, which is respectively disposed on the upper and lower surfaces of the supply chamber and the upper and lower surfaces of the receiving chamber; the magnetic attraction of the ring magnet fixes the supply chamber and the receiving chamber of the same drug absorption evaluation device unit relative to each other, so that the intestinal explant is stably clamped and forms a relatively sealed interface, or the ring magnet fixes the supply chamber and the receiving chamber of different drug absorption evaluation device units relative to each other, forming a sequentially arranged structure.

[0010] Furthermore, a positioning post is provided on the lower surface of the supply chamber, and a positioning hole is provided on the upper surface of the receiving chamber. The positioning post and the positioning hole cooperate with each other to ensure the alignment of the supply channel and the receiving chamber during the assembly process.

[0011] Furthermore, the microporous mesh is made of polyester, polytetrafluoroethylene, nylon, or polycarbonate, and the pore size of the microporous mesh is 0.2-0.8 mm.

[0012] Specifically, receiving fluid is added to the receiving chamber, a drug absorption evaluation device unit is assembled, and a supply fluid containing the drug to be tested is added to the supply chamber. Multiple assembled drug absorption evaluation device units are then sequentially placed into centrifuge containers, which are then placed in a centrifuge apparatus. By setting the centrifuge speed, different levels of hypergravity are applied to the drug absorption evaluation device units during the in vitro experiment. At predetermined time points, receiving fluid samples are extracted through sampling holes located on the side wall of the receiving chamber for subsequent drug detection. Analysis of the drug concentration in the receiving chamber under different centrifugation conditions can characterize the effect of hypergravity on intestinal drug absorption.

[0013] The rotational speed range of centrifuges is 0 < r ≤ 350 rpm. As long as the rotational speed is greater than 0, it is under hypergravity conditions. The higher the rotational speed, the higher the gravity value.

[0014] The present invention also provides a method for evaluating in vitro drug absorption under hypergravity. Using the aforementioned in vitro drug absorption evaluation device, a receiving liquid is added to the receiving chamber, a supply liquid containing the drug to be tested is added to the supply chamber, hypergravity is applied by centrifugation, and the receiving liquid sample obtained after centrifugation is analyzed to evaluate the in vitro intestinal absorption behavior of the drug.

[0015] The supply solution is a buffer solution containing the drug to be tested (preferably PBS buffer), and the receiving solution is a buffer solution (preferably PBS buffer).

[0016] Furthermore, ultraviolet-visible absorption spectroscopy was selected as the analytical method.

[0017] Furthermore, after obtaining the UV-Vis absorption spectrum of the receiving liquid sample, its absorbance value at a specific wavelength is collected. The drug concentration in the receiving liquid sample is calculated based on the absorbance value. Combined with the drug concentration in the supply liquid, the in vitro intestinal absorption behavior of the drug is evaluated.

[0018] During the experiment, the intestinal explant continuously secretes intestinal fluid components, which can interfere with the ultraviolet absorption signal. Therefore, after obtaining the ultraviolet-visible absorption spectrum of the receiving fluid sample, a spectral correction model is used to process the spectral interference data and correct the absorbance signal.

[0019] The spectral correction model was constructed as follows: a drug solution with a concentration of 31.25–500 μg / mL was mixed with the secretion fluid of the intestinal explant at a volume ratio of 0.0625–16:1, and ultraviolet-visible absorption spectroscopy was performed. The absorbance obtained from the ultraviolet-visible absorption spectroscopy was used as the input variable, and the actual concentration of the drug solution was used as the output label to construct a training dataset. A multiple linear regression model was established, and the multiple linear regression model was trained using the training dataset. The parameter-optimized multiple linear regression model was then used as the spectral correction model.

[0020] In actual in vitro drug absorption experiments, by applying the aforementioned model correction to the ultraviolet absorbance signal of the receiving chamber sample, the corrected true drug concentration value can be obtained. This effectively reduces the interference of intestinal secretion background on the detection results and improves the accuracy of drug concentration determination. Based on the correction results, the changes in intestinal tissue's drug absorption behavior under hypergravity conditions can be further analyzed.

[0021] Compared with the prior art, the beneficial effects of the present invention are as follows: (1) The drug absorption patterns obtained under normal gravity conditions are difficult to fully reflect the actual situation in hypergravity scenarios such as space launch and return and extraterrestrial exploration missions. Therefore, this invention selects hypergravity conditions for testing, aiming to clarify the changing patterns of human drug absorption behavior under special gravity environments. In the hypergravity in vitro drug absorption evaluation device of this invention, an intestinal explant is introduced as a biological barrier model for in vitro drug absorption, thereby improving the physiological relevance of in vitro evaluation at the tissue level.

[0022] (2) In the supergravity in vitro drug absorption evaluation device of the present invention, the setting of microporous mesh effectively reduces the interference of the deformation of intestinal explants under supergravity on the experimental results and improves the accuracy of the test.

[0023] (3) The present invention integrates the drug absorption evaluation device unit into a compact structure that is compatible with conventional centrifuge containers (such as centrifuge tubes), and combines it with conventional laboratory centrifugation equipment to achieve hypergravity loading, enabling in vitro hypergravity drug absorption research to be carried out without the need for large-scale special centrifugation facilities.

[0024] (4) The present invention can realize parallel experiments through a multi-unit magnetic connection structure, thereby increasing the throughput of in vitro drug absorption evaluation.

[0025] (5) The present invention establishes a spectral correction model to process spectral interference removal data, corrects absorbance signals, reduces the influence of intestinal secretions on detection results, improves the stability and reliability of detection results, and reduces dependence on complex analysis equipment such as LC-MS. Attached Figure Description

[0026] Figure 1 This is a structural diagram of an in vitro drug absorption evaluation device under ultragravity.

[0027] Figure 2 This is a schematic diagram of the receiving chamber.

[0028] Figure 3 This is a structural diagram of the supply room.

[0029] Figure 4 A in the diagram is a schematic diagram of the process of obtaining porcine jejunal tissue and preparing explants; B is the live and dead staining results of intestinal explants at different time points under in vitro culture conditions.

[0030] Figure 5 The images show the UV-Vis absorption spectra and correlation analysis results of intestinal secretions at different time points, where A and B are UV-Vis absorption spectra, and C is the correlation analysis result.

[0031] Figure 6 This is a schematic diagram illustrating the construction process of the spectral correction model.

[0032] Figure 7 This is a schematic diagram of the prediction results under various test drug conditions using a spectral correction model, where A represents metoprolol, B represents verapamil, and C represents propranolol.

[0033] Figure 8 Statistical analysis of drug absorption results under different hypergravity conditions.

[0034] Figure reference numerals: 1 Drug absorption evaluation device unit, 1-1 Supply chamber, 1-2 Receiving chamber, 1-3 Intestinal explant, 1-4 Microporous mesh, 1-5 Ring magnet, 1-6 Rubber stopper, 2 Centrifuge container, 3 Centrifuge equipment. Detailed Implementation

[0035] To make the objectives, features, and advantages of this invention more apparent and understandable, a detailed description is provided below through specific embodiments. Many specific details are set forth in the following description to provide a thorough understanding of the invention. However, the invention can be practiced in many other ways different from those described herein, and those skilled in the art can make similar modifications without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below. Technical features in various embodiments of the invention can be combined appropriately without mutual conflict.

[0036] Unless otherwise specified, the operating methods in the following examples are generally performed under conventional conditions or as recommended by the manufacturer. Contents not described in detail in this specification are prior art known to those skilled in the art. Unless otherwise specified, the experimental materials used in the examples below can be purchased from conventional biochemical reagent companies.

[0037] Example 1 like Figure 1 As shown, in this embodiment, the structure of the in vitro drug absorption evaluation device under hypergravity includes: a centrifuge device 3, a centrifuge container 2, and a drug absorption evaluation device unit 1; each centrifuge container 2 has multiple drug absorption evaluation device units 1 arranged in sequence inside. The drug absorption evaluation device unit 1 includes a supply chamber 1-1, a receiving chamber 1-2, an intestinal explant 1-3, and a microporous mesh 1-4. The supply chamber 1-1 and the receiving chamber 1-2 are arranged opposite each other, with the intestinal explant 1-3 sandwiched between them. The supply chamber 1-1 is provided with at least one supply channel (through-hole structure), and the receiving chamber 1-2 is provided with a receiving cavity that matches the supply channel. A microporous mesh 1-4 is provided above each receiving cavity to suppress the deformation of the intestinal explant under hypergravity conditions. The microporous mesh 1-4 is preferably a polyester microporous mesh with a pore size of 0.5 mm.

[0038] The drug absorption evaluation device unit also includes a fixing ring magnet 1-5, such as... Figure 2 As shown, the upper and lower surfaces of the receiving chamber 1-2 are respectively provided with annular grooves, the inner and outer diameters of which are 19.3 mm and 23 mm, respectively, for placing the annular magnet 1-5. A positioning hole is provided on the upper surface of the receiving chamber 1-2 to define the relative position between the supply chamber and the receiving chamber during assembly. The positioning hole is 12 mm from the central axis and has a diameter of 0.6 mm. Figure 3As shown, the upper and lower surfaces of the supply chamber 1-1 are also provided with annular grooves for placing the annular magnet 1-5. The lower surface of the supply chamber 1-1 is provided with a positioning post that mates with the positioning hole. In the same drug absorption evaluation device unit, the magnetic attraction of the annular magnet 1-5 presses the supply chamber 1-1 and the receiving chamber 1-2 together, thereby stably holding the intestinal explant and forming a sealed interface to realize the study of drug trans-tissue transport through the intestinal explant. The cooperation between the positioning post and the positioning hole further ensures accurate alignment during the assembly process, thus forming a multi-unit combined structure. At the same time, multiple drug absorption evaluation device units 1 can be axially connected through the annular magnet 1-5 and placed as a whole in the same centrifuge tube, so that the system can adapt to the size of commercially available conventional centrifuge tubes while realizing multi-channel parallel experiments, thereby meeting the needs of high-throughput in vitro drug absorption research. The supply chamber located at the top of the centrifuge tube is sealed with a sealing film to prevent liquid leakage during centrifugation.

[0039] Each individual drug absorption evaluation device unit employs a multi-channel structure. For example... Figure 2 As shown, the receiving chamber contains four independent receiving cavities, each with a diameter of 6.4 mm. The bottom of each cavity is a fully sealed structure. Four openable and closable sampling holes are located on the lower side wall of each receiving chamber, communicating with the lower part of each of the four receiving cavities. These sampling holes, with a diameter of 4.19 mm, remain sealed when not sampling. Each sampling hole is sealed with rubber stoppers 1-6 to maintain system tightness during centrifugation and to allow for continuous sampling of the receiving liquid during the experiment. Figure 3 As shown, the supply chamber has four supply channels corresponding to the dimensions of the receiving cavity channel. The magnetic attraction of the ring magnet and the cooperation between the positioning pin and the positioning hole ensure accurate alignment of the supply channels and the receiving cavity during assembly, thus forming a sealed and stable structure.

[0040] like Figure 4 As shown in Figure A, the intestinal explant used in this embodiment was prepared from fresh jejunal tissue obtained from pigs. During preparation, the serosa and muscle layer of the obtained intestinal tissue were peeled off, preserving the mucosal-associated tissue structures. The tissue was then longitudinally unfolded and rinsed with PBS solution containing 5% penicillin and antibiotics before use in drug transport experiments. If experiments were not to be performed immediately, the intact intestinal tissue could be cultured in Advanced DMEM / F-12 medium for preservation, maintaining tissue viability. When experiments were required, the serosa and muscle layer were peeled off, the tissue was washed, and assembled into the drug absorption evaluation device unit. Figure 4 As shown in B, the results of live-dead staining indicate that the intestinal explant can maintain its tissue viability for up to 7 days under in vitro culture conditions.

[0041] During the experiment, receiving fluid (PBS buffer) was added to the receiving chamber. The drug absorption evaluation device unit was assembled (the intestinal tissue explant was first placed above the receiving chamber, and then the supply chamber was assembled). Supply fluid containing the test drug (PBS buffer containing the test drug; the supply channel inside the supply chamber is a through-hole, preventing leakage after intestinal tissue explant assembly) was then added to the supply chamber. Multiple assembled drug absorption evaluation device units were then sequentially placed into a centrifuge container, and the upper surface of the supply chamber was sealed with a sealing film to prevent leakage during centrifugation. The centrifuge container was placed in a centrifuge, and different levels of hypergravity were applied to the drug absorption evaluation device units during the in vitro experiment by setting the centrifuge speed. At predetermined time points, receiving fluid samples were extracted through sampling holes on the side wall of the receiving chamber for subsequent drug concentration detection. Analysis of the drug concentration in the receiving chamber under different centrifugation conditions can be used to characterize the effect of hypergravity on intestinal drug absorption.

[0042] In this embodiment, the drug concentration of the sample obtained in the receiving chamber was detected using ultraviolet-visible absorption spectroscopy. Given that the intestinal explant continuously secretes intestinal fluid during the experiment, and that this secretion may interfere with the ultraviolet absorption signal, thus affecting the accurate determination of drug concentration, this invention establishes a spectral correction model to correct the detection signal. The study found that although the composition of intestinal secretions is complex, their ultraviolet-visible absorption spectra show high consistency across different time periods. Specifically, the intestinal explant secretions exhibit a stable characteristic absorption peak at approximately 258 nm. Figure 5As shown in AC, spectral correlation analysis was performed on intestinal secretion samples (n=3) from three different time periods. Their normalized absorption spectra were highly similar, and the Pearson correlation coefficients between the spectra from each time period were all greater than 0.99. Based on these results, the secretion from the intestinal explant can be considered a background absorption solution with stable characteristic absorption wavelengths. Based on this characteristic, during the model construction phase, the drug solution to be tested and the secretion from the intestinal explant were prepared into different concentration combinations to obtain a series of mixed solutions containing different drug concentrations and secretion levels (preferably, a drug solution with a concentration of 31.25–500 μg / mL was mixed with the secretion from the intestinal explant at a volume ratio of 0.0625–16:1). The mixed solutions were subjected to UV-Vis absorption spectroscopy measurements, and absorbance values ​​were collected at the characteristic wavelength of the intestinal secretion (258 nm) and the characteristic absorption wavelength of the drug to be tested, respectively. Specifically, the characteristic absorption wavelength of metoprolol was 274 nm, that of verapamil was 278 nm, and that of propranolol was 289 nm. Using absorbance values ​​at multiple wavelengths as input features and the actual drug concentration as the output label, taking metoprolol as an example, a training dataset was constructed with final concentrations of 15.625, 31.25, 62.5, 125, and 250 μg / mL in a mixed solution. A multiple linear regression model was then used to model the mapping relationship between absorbance features and the actual drug concentration, thereby obtaining spectral correction models for different drugs. Figure 6 ).

[0043] After obtaining the UV-Vis absorption spectrum of the receiving liquid sample, a spectral correction model was used to process the spectral data to remove interference and correct the absorbance signal. The drug concentration in the receiving liquid sample was calculated based on the absorbance value. Combined with the drug concentration in the supply solution, the in vitro intestinal absorption behavior of the drug was evaluated. Figure 7 As shown in AC, this method exhibits good prediction accuracy and stability under various drug conditions. In actual in vitro drug absorption experiments, by applying the above model correction to the UV absorbance signal of the receiving chamber sample, the corrected true drug concentration value can be obtained, thereby effectively reducing the interference of intestinal secretion background on the detection results and improving the accuracy of drug concentration determination. Based on the correction results, the changes in intestinal tissue drug absorption behavior under hypergravity conditions can be further analyzed.

[0044] like Figure 8As shown, in experiments using metoprolol, verapamil, and propranolol as representative model drugs, the detected drug concentrations in the receiving chamber all increased with increasing applied gravity levels, indicating that under the corresponding experimental conditions, the degree of intestinal absorption of these drugs is positively correlated with the gravity level. These results further validate the effectiveness of the present invention's hypergravity in vitro drug absorption evaluation device in studying intestinal drug absorption behavior under hypergravity conditions.

[0045] The embodiments described above provide a detailed explanation of the technical solutions of the present invention. It should be understood that the above descriptions are merely specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, additions, or similar substitutions made within the scope of the principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A device for evaluating in vitro drug absorption under ultragravity, characterized in that, The structure includes: Centrifugation equipment, centrifuge containers, and drug absorption evaluation device units; each centrifuge container contains multiple drug absorption evaluation device units arranged in sequence. The drug absorption evaluation device unit includes a supply chamber, a receiving chamber, an intestinal explant, and a microporous mesh. The supply chamber and the receiving chamber are arranged opposite each other, with the intestinal explant sandwiched in between. The supply chamber is provided with at least one supply channel, and the receiving chamber is provided with a receiving cavity that matches the supply channel. Each receiving cavity is provided with a microporous mesh above it to suppress the deformation of the intestinal explant under hypergravity conditions. At least one openable and closable sampling hole is provided on the lower side wall of the receiving chamber. The sampling hole communicates with the lower part of the receiving cavity and remains sealed when no sampling is being performed. Intestinal explants are prepared by washing animal jejunal tissue after removing the serosa and muscle layers.

2. The in vitro drug absorption evaluation device under ultragravity according to claim 1, characterized in that, The drug absorption evaluation device unit also includes a fixing component that fixes the supply chamber, receiving chamber, and intestinal explant in relative positions.

3. The in vitro drug absorption evaluation device under ultragravity according to claim 2, characterized in that, The fixing component is a ring magnet, which is respectively disposed on the upper and lower surfaces of the supply chamber and the upper and lower surfaces of the receiving chamber. The magnetic attraction of the ring magnet fixes the supply chamber and the receiving chamber of the same drug absorption evaluation device unit relative to each other, or the ring magnet fixes the supply chamber and the receiving chamber of different drug absorption evaluation device units relative to each other, forming a sequentially arranged structure.

4. The in vitro drug absorption evaluation device under ultragravity according to claim 1, characterized in that, The lower surface of the supply chamber is provided with positioning posts, and the upper surface of the receiving chamber is provided with positioning holes. The positioning posts and positioning holes cooperate with each other.

5. The in vitro drug absorption evaluation device under ultragravity according to claim 1, characterized in that, The microporous mesh is made of polyester, polytetrafluoroethylene, nylon or polycarbonate, and the pore size of the microporous mesh is 0.2-0.8 mm.

6. A method for evaluating in vitro drug absorption under ultragravity, characterized in that, Using the in vitro drug absorption evaluation device based on any one of claims 1-5, a receiving liquid is added to the receiving chamber, a supply liquid containing the drug to be tested is added to the supply chamber, centrifugation is performed to apply hypergravity, and the receiving liquid sample obtained after centrifugation is analyzed to evaluate the in vitro intestinal absorption behavior of the drug.

7. The method for evaluating in vitro drug absorption under ultragravity according to claim 6, characterized in that, The supply solution is a buffer solution containing the drug to be tested, and the receiving solution is a buffer solution.

8. The method for evaluating in vitro drug absorption under hypergravity according to claim 6, characterized in that, The analytical method used was ultraviolet-visible absorption spectroscopy.

9. The method for evaluating in vitro drug absorption under hypergravity according to claim 8, characterized in that, After obtaining the UV-Vis absorption spectrum of the receiving liquid sample, its absorbance value at a specific wavelength is collected. The drug concentration in the receiving liquid sample is calculated based on the absorbance value. Combined with the drug concentration in the supply liquid, the in vitro intestinal absorption behavior of the drug is evaluated.

10. The method for evaluating in vitro drug absorption under hypergravity according to claim 9, characterized in that, After obtaining the UV-Vis absorption spectrum of the receiving liquid sample, the spectral correction model is used to process the spectral interference removal data and correct the absorbance signal. The spectral correction model was constructed as follows: a drug solution with a concentration of 31.25–500 μg / mL was mixed with the secretion fluid of the intestinal explant at a volume ratio of 0.0625–16:1, and ultraviolet-visible absorption spectroscopy was performed. The absorbance obtained from the ultraviolet-visible absorption spectroscopy was used as the input variable, and the actual concentration of the drug solution was used as the output label to construct a training dataset. A multiple linear regression model was established, and the multiple linear regression model was trained using the training dataset. The parameter-optimized multiple linear regression model was then used as the spectral correction model.

Images